CS Paper Radar

Ensemble Classification and Cancer-Specific Gene Signatures from Quality-Aware Hybrid Gene Selection in TCGA RNA-Seq data

Tareque Mohmud Chowdhury, Abu Raihan Mostofa Kamal

cs.LG ·submitted 2026-10-31 00:05 UTC · v1

Abstract

Gene-expression classifiers of cancer type are usually developed and validated within one cohort using random splits. Starting from a quality-aware hybrid Boruta selector from earlier work, we developed and evaluated ensemble classifiers and cancer-specific gene signatures. Using 10,469 TCGA tumours of 33 types, we compared five learners and three ensembles under decision rules fixed in advance, reran the selection in site-grouped cross-validation, transferred a breast-cancer subtype panel to 3273 tumours of the independent SCAN-B cohort, and built five-gene stage~I tumour versus adjacent-normal panels for nine cancer types. Logistic regression (LR) was the most accurate and best-calibrated single learner (balanced accuracy 0.943 on the locked test set). Stacking added at most 0.006 with 1000 genes but improved on LR in every fold with a minimal 100-gene panel; a hierarchical model did not reduce within-group confusion. Site-grouped validation lowered balanced accuracy by 0.027, almost entirely in colon and rectal cancer (0.008 without them and the untestable LAML). On SCAN-B, the subtype panel reached 0.855, close to the 50 PAM50 genes (0.876). Stage~I panels reached ROC AUC >= 0.99 in held-out patients and detected most later-stage tumours. Ensembles help most with a minimal panel; with 1000 genes, a calibrated linear model suffices.

Comment
17 pages, 6 figures, 3 tables and 1 supplementary file

Closest papers

Nearest neighbours by meaning across the whole index.

Tree Depth and Sample-Quality-Associated Features: Two Hidden Factors in Boruta Selection for RNA-Seq Data Classification

cs.LG ·2026-10-23 ·Tareque Mohmud Chowdhury, Abu Raihan Mostofa Kamal
similarity 0.66
Abstract · 19 Pages, 6 Figures, 4 Tables

Random Forest--based selectors such as Boruta depend on tree depth, yet Boruta's most used implementation, BorutaPy, recommends depths of 3 to 7 without published evidence. We tested the effect of depth using pan-cancer data from The Cancer Genome Atlas (10,469 tumors, 33 cancer types) and breast cancer PAM50 subtyping (981 tumors, 5 subtypes). Label-dependent steps were fitted inside training folds, effects were measured against seed-to-seed variation, and each task kept a locked test set. In pan-cancer data, depth 5 changed the selection far more than a new seed did: the top-500 Jaccard overlap with unlimited depth was 0.37, against 0.84 (depth 5) and 0.93 (unlimited) between seeds. Depth-5 trees confirmed 472 instead of 1,659 genes, covered fewer large-class markers (16% vs 62%) and gave less accurate 50-gene panels (balanced accuracy 0.809 vs 0.889). The effect vanished once the cap reached 61 to 76% of the median depth of unrestricted trees, a depth that depends mainly on the number of classes, not sample size. In PAM50 subtyping (median depth 12) the effect was small, and leaving depth uncapped cost no accuracy in either task. It replicated in a second cross-validation repeat and under permutation importance. About a third of pre-filtered candidates correlated within class with the number of detected genes, a sample-quality measure; a within-class filter removed them without loss of test accuracy (0.943 vs 0.942 balanced accuracy, 1,000 genes). We recommend uncapped trees, or a cap above 75% of the realized median depth, and a within-class quality filter before Boruta.

0.48

Label-Space Mismatch Distorts Cross-Cohort Evaluation in Breast Cancer Molecular Subtyping

cs.LG cs.AIq-bio.QM ·2026-10-18 ·Suxing Liu, Byungwon Min, Zhijian Zheng, Jiahao Wang
similarity 0.61
Abstract

Cross-cohort evaluation of breast cancer subtype classifiers is unreliable when source and target cohorts use different annotation standards: METABRIC labels six classes, PAM50 defines five, and a claudin-low prediction cannot be correct under a five-class standard. A classifier transferred from 1,369 METABRIC patients (train n=958) to TCGA-BRCA (n=987) and GSE21653 (n=266) separates three evaluation operations routinely conflated in cross-site comparisons. (1) Label-space restriction - an evaluation-rule change, not a retraining gain - is the dominant correction (73.76%->79.74% on TCGA-BRCA; 63.16%->68.42% on GSE21653); (2) EM prior correction on the reconciled space is an optional calibration step (Brier fidelity up, macro F1 down; to 80.65% and 74.06%); and (3) the target label space is not recoverable from unlabelled predictions (EM retains prior 0.0751 on the absent class; calibrated detectors fail), so compliance must come from cohort documentation. The protocol exposes why internal validation overstates cross-cohort value: multimodal fusion gains do not transfer (no configuration beats mRNA alone, n=694; McNemar p=0.13-1.00), and the genomic panel adds nothing to pathological complete response prediction over clinical variables (DeltaAUC = +0.0045). Clinically, without label-space compliance, cross-site accuracy comparisons misattribute annotation-standard differences to model skill; Luminal A/B and claudin-low boundary errors map to distinct treatment decisions; and subtype accuracy is a weaker portable endpoint than survival discrimination (external C-index 0.577-0.584). Reporting the cohort's allowed label set and applying label-space compliance are therefore prerequisites before any cross-cohort performance claim.

0.26

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.60
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

Benchmarking Active Spot Selection for Cost-Efficient Spatial Transcriptomics

cs.CV cs.LGq-bio.OT ·2026-09-23 ·Zheyu Zhu, Junchao Zhu, Fengbei Liu, Tianyuan Yao, Gelei Xu +5 more
benchmark similarity 0.59
Abstract

Spatial transcriptomics (ST) measures gene expression in tissue context, but dense capture grids can be costly and may repeatedly sample morphologically similar regions. Most active learning strategies were developed for categorical labels and independent samples. We conduct a retrospective pool-based benchmark of active learning versus uniform Random sampling for ST, where expression vectors are high-dimensional and continuous and candidates are spatially correlated. Using two fully profiled public ST cohorts, we mask candidate expression vectors and simulate multi-round selection with uncertainty-based Monte Carlo dropout (MC-dropout) and temporal output discrepancy (TOD), and diversity-based CoreSet and TypiClust-inspired selection. We compare 160 completed configurations at 5%, 10%, 30%, and 50% of the fold-wide training spot pool under patient-level cross-validation, with a separate full-label reference. Within each budget, strategies share the selection schedule, morphology-to-expression predictor, and optimization protocol. We assess mean per-gene within-slide Pearson correlation coefficient (PCC), expression-cluster agreement, and Moran's I fidelity. On HER2-positive breast cancer, pooled mean PCC differences from Random across the four active strategies were -0.0176, -0.0117, +0.0056, and +0.0057 at 5%, 10%, 30%, and 50%, respectively. On cutaneous squamous cell carcinoma (cSCC), three strategies were below Random at 5%, and all four were below Random at 10%. On HER2-positive breast cancer, CoreSet and MC-dropout had lower PCC but higher expression-cluster agreement than Random at the two smallest budgets; this pattern did not reproduce on cSCC. Under the reported fixed training horizons, the evaluated active strategies do not consistently improve on Random at small budgets, and rankings depend on the evaluation measure.

0.32

Benchmarking Machine-Learning Classifiers for Neoantigen Immunogenicity Prediction and the Limits of SHAP Interpretability

cs.AI cs.LG ·2026-10-31 ·Ramon Gonzalez
benchmark similarity 0.58
Abstract · 23 pages, 8 figures, 7 tables

Personalized cancer vaccines require prioritizing, among hundreds of candidate mutant peptides, the few that will induce a T-cell response. This study asks what general-purpose machine learning achieves on that task, and whether the features such models identify as important can be trusted. We make three contributions. The first is a benchmark of sixty models: twelve supervised classifier families, each in five configurations, evaluated on the Immunogenic Tumor Specific Neoantigen database (ITSNdb; 199 experimentally validated neoantigens, 129 immunogenic and 70 non-immunogenic). All sixty are compared under one stratified k-fold cross-validation protocol, in which the data used to choose a configuration are never the data used to score it. The second is an interpretability study that combines SHAP with feature ablation. The third is a shuffled-label control that tests whether a SHAP value has been earned. Two results follow, and both run against current practice. First, the classical linear models lead the ranking. The gradient-boosted ensembles and neural networks that dominate recent work bring no advantage. Second, SHAP can fail on high-cardinality categorical features. Ablation establishes the presenting HLA allele as the dominant input and the source gene as dispensable. SHAP reports the opposite, assigning 68.7% to 81.7% of its total value to the source gene in every model that gives each gene its own weight. Shuffling the gene labels at random among the peptides resolves the contradiction: the meaningless column earns the same SHAP value as the real one. That value measures only that ITSNdb contains 173 genes for 199 peptides. We therefore recommend that SHAP values for high-cardinality categorical annotations in cohorts of this size always be reported against such a shuffled-label control, and we describe one in full.

0.35

Beyond Discrimination: Evaluating Probability Calibration in Radiomics-Image Fusion for Renal Cell Carcinoma Classification

eess.IV cs.AIcs.CVq-bio.QM ·2026-10-09 ·Yuan Liang, Morgan May, Abraham Campbell, Sourav Bhattacharjee, Simon Caton +1 more
top venue similarity 0.57
Abstract · 12 pages. 1 figure. Accepted at the 2026 Irish Conference on Artificial Intelligence and Cognitive Science (AICS 2026). Proceedings forthcom…

Reliable probability estimates are important for the clinical interpretation of machine-learning classifiers, yet radiomics--image fusion models for renal cell carcinoma (RCC) are commonly evaluated primarily by discrimination. Using 396 patients from the KiTS23 dataset, we evaluated whether adding radiomics to four image-model families improved probabilistic performance in addition to discrimination. Seventeen individual models and four probability-average ensembles were assessed using discrimination, probability calibration, and proper scoring measures. Across 12 matched image-only versus fusion comparisons, AUC and AP improved in all 12, while Brier score and negative log likelihood (NLL) improved in 11 of 12 and expected calibration error (ECE) in eight of 12. The 3D MedVAE gated-fusion model achieved the strongest overall individual-model profile. Probability averaging across concatenation, cross-attention, and gated fusion produced favourable point estimates across all five primary metrics relative to image-only models in all four families, although paired-bootstrap support was stronger for Brier score and NLL than for ECE. These findings show that radiomics--image fusion can improve probabilistic prediction quality beyond discrimination, while calibration behaviour varies across image architectures and fusion strategies. We show that our proposed probability-average ensemble models improve discrimination and calibration simultaneously across all architectures in the study.

0.38

ARISE: An adaptive residual-informed stability ensemble for feature selection in small-sample biomedical omics

cs.LG stat.ML ·2026-08-14 ·Zardad Khan, Amjad Ali, Naz Gul, Saeed Aldahmani
similarity 0.56
Abstract · 30 pages, 6 figures

Objective: Small-sample molecular classification requires feature selectors that identify predictive, stable, and nonredundant subsets for binary and multiclass outcomes. We propose ARISE (Adaptive Residual-Informed Stability Ensemble), which integrates complementary relevance signals, class-balanced stability assessment, residual-informed redundancy control, and multiclass pairwise coverage. Methods: ARISE combines seven percentile-normalized relevance components through 15 predefined profiles, adaptively weighted by nested inner cross-validation. It was evaluated on five molecular datasets, eight feature-set sizes, three fixed classifiers (k-nearest neighbours, support vector machine, and random forest), and six filter comparators. Generalization was estimated by five-fold outer cross-validation repeated 50 times using balanced accuracy, macro-F1, and Cohen's kappa. Results: Across 210,000 held-out assessments, ARISE ranked first in all 15 dataset-metric combinations. Equal-dataset means were 0.793 for balanced accuracy, 0.776 for macro-F1, and 0.725 for kappa, exceeding the strongest aggregate comparator by 0.022, 0.023, and 0.028, respectively. Performance remained strong across compact feature sets, although the optimal budget differed by dataset. Conclusion: ARISE provides a transparent, adaptive framework that jointly addresses relevance, stability, redundancy, and multiclass discrimination. Its consistent results across datasets, classifiers, metrics, and feature-set sizes support further evaluation for small-sample molecular classification.

0.10

TIRA: Tumor Immune Representation Adaptation for Zero-Shot Cross-Cancer MSI and TMB Prediction

cs.CV ·2026-10-07 ·Dasari Naga Raju
similarity 0.56
Abstract

Microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB-H) are clinically relevant biomarkers, yet their histopathological prediction remains challenging when models are transferred across morphologically distinct cancer types. Immune-associated spatial patterns can persist across cancers despite these morphological differences, but foundation-model-based predictors trained on a single cancer do not explicitly use this information, limiting cross-cancer generalization. To address this limitation, we propose TIRA (Tumor Immune Representation Adaptation), a target-free framework that refines frozen foundation-model representations using spatial immune topology, without requiring target-domain data during model development or test-time adaptation. TIRA uses a topology-supervised biology representation to condition tile-level attention while pooling only morphological features for joint MSI and TMB prediction. We train TIRA on TCGA-COAD+READ and evaluate it zero-shot on CPTAC-COAD, TCGA-STAD, TCGA-UCEC, and CPTAC-UCEC, covering cross-site, cross-cancer, and combined cross-cancer-site distribution shifts under UNI2, CONCH, and Virchow2. With UNI2, TIRA improved zero-shot AUROC on TCGA-STAD from 0.633 to 0.766 for MSI and from 0.651 to 0.772 for TMB. Source-derived spatial immune topology improved the cross-cancer robustness of frozen pathology foundation-model representations.

0.04